Shares of ARGENX SE-ADR (NASDAQ:ARGX) have earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $29.67 for the company, according to Zacks. Zacks has also given ARGENX SE-ADR an industry rank of 99 out of 265 based on the ratings given to its competitors.

A number of research analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating on shares of ARGENX SE-ADR in a report on Monday, June 12th. Cowen and Company assumed coverage on shares of ARGENX SE-ADR in a report on Monday, June 12th. They set an “outperform” rating for the company. Finally, JMP Securities assumed coverage on shares of ARGENX SE-ADR in a report on Monday, June 12th. They set an “outperform” rating and a $33.00 price objective for the company.

ARGENX SE-ADR (NASDAQ:ARGX) traded down 0.96% during trading on Friday, hitting $20.70. 13,388 shares of the stock were exchanged. ARGENX SE-ADR has a 52 week low of $17.33 and a 52 week high of $25.00. The firm’s market cap is $556.23 million. The firm’s 50-day moving average is $20.71 and its 200 day moving average is $20.72.

WARNING: “Zacks: ARGENX SE-ADR (ARGX) Receives Average Recommendation of “Strong Buy” from Brokerages” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/04/zacks-argenx-se-adr-argx-receives-average-recommendation-of-strong-buy-from-brokerages.html.

A number of institutional investors have recently added to or reduced their stakes in ARGX. FMR LLC purchased a new position in ARGENX SE-ADR during the second quarter worth about $15,990,000. VHCP Management II LLC purchased a new position in ARGENX SE-ADR during the second quarter worth about $13,615,000. Federated Investors Inc. PA purchased a new position in ARGENX SE-ADR during the second quarter worth about $9,545,000. Franklin Resources Inc. purchased a new position in ARGENX SE-ADR during the second quarter worth about $7,424,000. Finally, AXA purchased a new position in ARGENX SE-ADR during the second quarter worth about $3,190,000. Institutional investors and hedge funds own 23.53% of the company’s stock.

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on ARGENX SE-ADR (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related stocks with our FREE daily email newsletter.